Once a brokerage account has access to the New York Stock Exchange, buying Boston Scientific comes down to one order for its common stock, ticker BSX. Behind the ticker is a device maker that has leaned hard into the heart: Electrophysiology, built around the Farapulse ablation system, went from about 5.6% of sales in 2023 to 16.6% in 2025. There is no cash dividend. This guide covers the business, the order itself and what 2026 changed: slower growth, a cyberattack and a pending deal for Penumbra.
What Does Boston Scientific Do?
Boston Scientific makes catheters, implants, stents and scopes that let doctors work through a blood vessel or small opening instead of open surgery. The 10-K describes it as "a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties." Formed in 1979 and incorporated in Delaware, it is based in Marlborough, Massachusetts, sells in 127 countries and had about 59,000 employees at the end of 2025.
It reports two segments. MedSurg covers Endoscopy (stents, clips and single-use scopes for the digestive tract), Urology (kidney-stone tools, prostate treatments and, via Axonics, bladder and bowel control implants) and Neuromodulation (spinal cord and brain stimulators). Cardiovascular, the larger side, adds coronary devices such as the AGENT drug-coated balloon, defibrillators, pacemakers, liver cancer therapies and the two franchises that now define the stock.
Watchman closes off the left atrial appendage in people with non-valvular atrial fibrillation and a raised stroke risk, as an alternative to long-term blood thinners; the company calls it "the leading device in percutaneous LAAC globally." Farapulse treats atrial fibrillation with pulsed field ablation. It launched in the US in early 2024 and is "now the predominant component of our Electrophysiology business unit and revenue."
Recent purchases include Silk Road Medical (carotid stroke prevention, September 2024), Axonics (November 2024) and Nalu Medical (chronic pain, January 2026). From 1 January 2027 the company plans three segments: Interventional Therapies, Rhythm Solutions and MedSurg.
How Boston Scientific Makes Money
Revenue comes mainly from single-use devices sold to hospitals and clinics; buying groups and hospital networks account for a "substantial portion," though no single customer exceeded a tenth of sales from 2023 to 2025. Net sales rose 19.9% in 2025, or 15.8% organically, excluding currency and recent acquisitions.
| Business unit | Segment | Share of 2025 net sales | Growth vs 2024 |
|---|---|---|---|
| Interventional Cardiology and Vascular Therapies | Cardiovascular | 23.1% | 10.5% |
| Electrophysiology | Cardiovascular | 16.6% | 74.6% |
| Endoscopy | MedSurg | 14.5% | 8.5% |
| Urology | MedSurg | 13.5% | 23.1% |
| Cardiac Rhythm Management | Cardiovascular | 11.6% | 2.3% |
| Watchman | Cardiovascular | 9.8% | 29.2% |
| Neuromodulation | MedSurg | 6.0% | 8.4% |
| Interventional Oncology and Embolization | Cardiovascular | 5.0% | 16.4% |
Worked out from the fiscal 2025 10-K revenue note, to one decimal.
The 10-K credits the growth above all to Electrophysiology, up 74.6% as treatment moved to pulsed field ablation; Watchman added 29.2%. Urology's jump mostly reflects Axonics; its organic growth was 4.7%. The United States supplied 64.1% of net sales. Gross margin was 69.0%, research and development took 10.2% of sales, and before corporate costs and amortization the segments earned similar margins: 33.2% for MedSurg and 32.4% for Cardiovascular.
BSX Stock at a Glance
| Field | BSX |
|---|---|
| Exchange | New York Stock Exchange (NYSE) |
| Ticker | BSX |
| Share class | Common stock; no other equity on the 10-K cover |
| Also listed | Senior notes due 2027, symbol BSX27 |
| Index membership | S&P 500 |
| Headquarters | Marlborough, Massachusetts |
| Incorporated | Delaware, formed 1979 |
| Fiscal year | Calendar year |
| Dividend policy | None paid in 2023 to 2025, none currently intended |
| Stock splits | November 1998 and November 2003, each two-for-one |
| SEC identifier | CIK 885725 |
For live price, market value and volume, open the Boston Scientific stock page on Bitbase.
How to Buy Boston Scientific Stock
As a US company, Boston Scientific has no depositary receipt to consider:
1. Choose a broker with NYSE access, noting which company will hold your shares and under which regulator.
2. Complete the account checks. Non-US clients are normally asked for IRS Form W-8BEN, which establishes foreign status.
3. Fund it, counting the currency conversion rate as part of the cost.
4. Search BSX and confirm the name. BSX27 is a different security: the company's senior notes, which are debt.
5. Pick an order type. According to FINRA, a market order "provides the most certainty that your order will be executed," but "you might not get the price you saw or were originally quoted." A limit order buys "at or better than a specified price," with "a chance your order doesn't get executed at all." See how market orders fill.
6. Set the size. Some brokers sell fractional shares for a fixed cash amount; ask how yours handles voting and transfers for them.
Withholding for non-US holders. In the IRS's words, "most types of U.S. source income received by a foreign person are subject to U.S. tax of 30%," though treaties can lower that. With no dividend it has little to act on; your home country's tax on gains is likelier to matter.
Through funds. As an S&P 500 member, BSX sits in funds that track the index and in the Health Care Select Sector SPDR fund (XLV).
What Moves BSX Stock
Electrophysiology's pace. Second-quarter 2026 Electrophysiology sales grew 9.0%, and the 10-Q cited "increased competition within our Electrophysiology business unit"; Abbott, for one, sells its own pulsed field system, Volt, as our guide to Abbott stock notes. A shareholder class action filed in March 2026 concerns what the company said about US electrophysiology growth.
Watchman volumes. Watchman grew 29.2% in 2025 but 4.3% in the second quarter of 2026, which the 10-Q put down partly to slower procedures. In March 2026 the company reported that CHAMPION-AF, comparing Watchman FLX with blood thinners as a first-line option, "met all primary and secondary safety and efficacy endpoints."
The August cyberattack. An incident detected on 25 August 2026 disrupted manufacturing and order shipping worldwide. An 8-K on 8 September called it "likely to have a material impact" on third-quarter and full-year results, and July's guidance would probably be missed; third-quarter net sales grew 1.5%.
The Penumbra deal. In January 2026 Boston Scientific agreed to buy Penumbra, a maker of blood-clot removal systems, paying with cash, new debt and its own shares. The FTC asked for more information in March, Penumbra holders approved in May, and an October 2026 release still referred to the "anticipated close."
China. Urology was roughly flat in the first half of 2026, partly because of "volume-based-procurement in China," where the 10-K says local device makers "may benefit from their status as local suppliers."
Where Boston Scientific's Growth Could Stall
Four Item 1A headings in the 10-K matter most for a BSX holder:
Competition. The company may "not be able to keep pace with the rapid technological changes in the medical devices industry or low-cost competitive offerings." With 2025 growth led by two franchises, a better or cheaper rival device is the central risk.
Pricing. Cost containment, payment reforms and consolidation among buyers "could decrease the demand for our products."
Integration. "Failure to integrate acquired businesses into our operations successfully could adversely affect our business," a risk that grows with each deal, Penumbra above all.
Regulation and litigation. Device rules can bring "the recall or seizure of previously approved products," and product liability claims remain over transvaginal mesh, most of them settled or close to it, and over spinal cord stimulators, whose federal cases were consolidated in June 2026.
The share adds its own risks: without a dividend, returns depend on the price alone, a single stock stakes the money on one company's results, and holding it from another currency adds exchange-rate swings.
How to Research BSX Yourself
Boston Scientific's SEC identifier is CIK 885725; its annual 10-K, quarterly 10-Qs and 8-Ks for events such as the cyber incident are all on EDGAR. In the 10-K, Item 1 covers products, Item 1A risks, and the revenue note splits sales by business unit and region. The investor site, investors.bostonscientific.com, carries call webcasts.
One caution: segments change on 1 January 2027, and after the late-2025 reorganization earlier periods were revised, so check the basis of any comparison. Other companies are on the full list of US stock pages on Bitbase.
Boston Scientific Stock FAQ
Does Boston Scientific pay a dividend?
No. It paid no cash dividend in 2023, 2024 or 2025, and the 10-K says "currently we do not intend to pay cash dividends on our common stock." In 2026 it turned to buybacks instead, including an accelerated share repurchase settled in June.
Can I buy Boston Scientific stock with crypto?
Not directly. BSX trades through brokers and settles in US dollars: you would sell the crypto, move the dollars to your broker and then buy, and that sale may be taxed where you live. A share is also a registered stake with voting rights, unlike a crypto asset.
Is BSX in the S&P 500?
Yes. Boston Scientific appears in State Street's 29 October 2026 holdings file for SPY, its S&P 500 ETF, and in the file for XLV.
Has Boston Scientific stock ever split?
Yes, twice according to its filings: two-for-one on 30 November 1998 and again on 5 November 2003. Per-share data from before those dates must be restated to compare.
What are Farapulse and Watchman?
Farapulse is a pulsed field ablation system for atrial fibrillation; Watchman is an implant that seals off the left atrial appendage to lower stroke risk for some patients without lifelong blood thinners. Their business units made up 26.3% of 2025 net sales and were the two fastest-growing that year.
Conclusion
Placing a BSX order is routine; judging what you buy takes more work. Much of the story runs through two heart franchises that slowed in 2026, a deal still pending in October and recovery from a cyberattack, with no dividend to cushion a weak stretch. The latest 10-K, 10-Q and 8-Ks date each of those threads; read them before sizing a position.
Related reading
Other Bitbase articles on this topic:
- How to Buy Becton Dickinson Stock (BDX): Waters Deal and Dividend
- How to Buy Cardinal Health Stock (CAH): CVS, Generics, Opioids
- How to Buy Cencora Stock (COR): Ex-AmerisourceBergen, Walgreens
- How to Buy HCA Healthcare Stock (HCA): Payers, Texas and Florida
Disclaimer: This article is educational content from Bitbase Academy, provided for information only. It explains what a company or fund does and how the instruments referenced here differ from one another; it does not constitute investment, trading, tax, or financial advice, and it is neither a recommendation nor an endorsement of any security, token, or trading strategy. A tokenized stock is issued by a third party and is designed to give economic exposure to an underlying asset: it is not a share, it carries no shareholder rights, and it depends on the issuer's structure, eligibility rules, and redemption terms, which the issuer can change. Perpetual futures are leveraged derivatives that hold no underlying asset and can be liquidated, and trading hours, product availability, and eligibility differ by instrument and by jurisdiction and can change at any time. Written as of October 2026; verify everything yourself through company filings, the issuer's own documentation, and the product pages of the venue you trade on.
References
[1] Boston Scientific Form 10-K for fiscal 2025 (SEC EDGAR) www.sec.gov
[2] Boston Scientific Form 10-Q for the quarter ended 30 June 2026 (SEC EDGAR) www.sec.gov
[3] Boston Scientific Form 8-K, 8 September 2026 (SEC EDGAR) www.sec.gov
[4] Boston Scientific third-quarter 2026 results, 28 October 2026 (Form 8-K) www.sec.gov
[5] Boston Scientific release, 7 October 2026: segments from 2027 (Form 8-K) www.sec.gov
[6] Boston Scientific release, 28 March 2026: CHAMPION-AF (Form 8-K) www.sec.gov
[7] Boston Scientific Form 10-K for 2004 (SEC EDGAR) www.sec.gov
[8] Boston Scientific 2000 annual report financials (SEC EDGAR) www.sec.gov
[9] State Street, SPY daily holdings, 29 October 2026 www.ssga.com
[10] State Street, XLV daily holdings, 29 October 2026 www.ssga.com
[11] FINRA, Order Types www.finra.org
[12] IRS, NRA Withholding www.irs.gov






